A meeting on Capitol Hill in Washington, D.C. today heard about one person’s struggle with cystic fibrosis and her hope for precision medicine to provide a cure. . . . → Read More: Precision Medicine, “My Hope for the Future”
|
|||||
A meeting on Capitol Hill in Washington, D.C. today heard about one person’s struggle with cystic fibrosis and her hope for precision medicine to provide a cure. . . . → Read More: Precision Medicine, “My Hope for the Future” Agricultural scientists in Ohio are developing a process for converting common food waste into materials used in car tires, and filed a patent for these techniques. . . . → Read More: Process Converts Food Waste to Auto Tire Materials A system designed to sample the air in homes of people with allergies found a number of airborne allergens in residences that previously went undetected by other devices. . . . → Read More: Air Sampling Device Finds Unreported Allergens A clinical trial began recruiting participants with advanced tumors to test a compound that helps treatments for cancer harnessing the immune system. . . . → Read More: Trial Underway to Test Cancer Immunotherapy Aid Academic and industry researchers demonstrated production of therapeutic antibodies inside cells of lab mice, offering a simpler and lower-cost alternative to monoclonal antibodies. . . . → Read More: Messenger RNA Engineered to Produce Antibodies Two biotechnology companies are collaborating to discover new vaccines protecting against Ebola and Zika viruses that present global threats to public health. . . . → Read More: Biotech Companies to Discover Ebola, Zika Vaccines A patch worn on the arm providing stimulation to nerve cells was shown in a clinical trial to reduce the amount of pain experienced by people with migraines. . . . → Read More: Mobile App-Controlled Patch Reduces Migraine Pain Freenome, a company applying machine learning to analysis of liquid biopsies, is raising $65 million in its first round of venture financing. . . . → Read More: Cancer Blood Test Company Raises $65M in Early Funds A clinical trial testing synthetic immune system cells shows after 6 months the cells can generate a full or partial response in many patients with non-Hodgkin lymphoma. . . . → Read More: Engineered T-Cells Shown Reducing Non-Hodgkin Lymphoma |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |